Skip to main content
Laurus Labs Limited logo

Laurus Labs Limited — Investor Relations & Filings

Ticker · LAURUSLABS ISIN · INE947Q01028 LEI · 335800S8HO8QRYP3VQ26 BSE.NS Manufacturing
Open in API
Filings indexed 707 across all filing types
Latest filing 2021-10-21 Call Transcript
Country IN India
Listing BSE.NS LAURUSLABS

About Laurus Labs Limited

https://www.lauruslabs.com/

Laurus Labs Limited is a research-driven organization focused on the development and manufacturing of active pharmaceutical ingredients (APIs), finished dosage forms (FDF), and specialized synthesis services. The company operates across several key therapeutic areas, including anti-retroviral (ARV), oncology, cardiovascular, and anti-diabetic treatments. Through its contract development and manufacturing organization (CDMO) division, it provides integrated drug development solutions to global partners. The company also maintains a biotechnology segment dedicated to recombinant products. Leveraging advanced research and development capabilities alongside large-scale manufacturing infrastructure, the firm emphasizes process chemistry innovation and cost-efficient production to serve diverse global healthcare markets.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is an announcement for a conference call regarding Laurus Labs Ltd.'s Q2 FY22 results scheduled on October 29, 2021. It includes details about the call timing, dial-in numbers, and a brief company description. There is no actual financial data or detailed financial report included in the text. The document is clearly a notice for an upcoming earnings call rather than the transcript or the earnings release itself. Therefore, it fits best into the category of Call Transcript (CT) announcements, as it pertains to a conference call about quarterly results.
2021-10-21 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for omitted pictures and no substantive text or financial data. The true document length is only 107 characters, indicating it is extremely short and contains no report content. There is no indication of any report, announcement, or filing type. Given the lack of content, this document does not fit any specific report category and defaults to Regulatory Filings (RNS) as a fallback category.
2021-10-20 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a confirmation certificate pursuant to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. It confirms that no securities were received for dematerialization during the quarter ended September 2021. The document is short (1504 characters) and is a regulatory compliance certificate rather than a financial report or announcement. It does not contain financial data or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which covers officer certifications and compliance documents.
2021-10-11 English
Trading Window
Regulatory Filings Classification · 100% confidence The document text is extremely short (116 characters) and contains no substantive content, only placeholders for omitted pictures. There is no financial data, report content, or any descriptive text. Given the lack of any report or announcement content, this document does not fit any specific report category. It is best classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings without meaningful content.
2021-09-30 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 70% confidence The document is extremely short (213 characters) and contains only a brief table referencing a virtual investor summit meeting with no substantive financial data, analysis, or detailed report content. It appears to be a summary or announcement of an investor interaction event rather than a full report or detailed presentation. There is no indication of financial statements, management discussion, or regulatory filings. Given the brevity and nature, it best fits as an Investor Presentation (IP) or possibly a Regulatory Filing (RNS). However, since it is a summary of an investor meeting, the closest specific category is Investor Presentation (IP). Confidence is moderate due to limited content but the context aligns best with IP.
2021-09-17 English
Press Release
Regulatory Filings
2021-09-14 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.